AETHLON MEDICAL INC and Indaptus Therapeutics, Inc. Common Stock
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Open AEMD dashboard ↗Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Open INDP dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →